Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Arbutus Biopharma Corp (ABUS)

NASDAQ
Currency in USD
Disclaimer
2.750
0.000(0.00%)
Closed
Pre Market
2.840+0.090(+3.27%)

ABUS Comments

Latest Tweet by Acuitas Therapeutics : Our partner, BioNTech SE announced the selection of their lead vaccine candidate against COVID-19 and the start of the next phase of studies. We’re proud that they are using our lipid nanoparticle delivery system. license agreement between Genevant and Arbutus.!!
no problem,next earnings pozitiv:)
come on man arbutus
guys bad Q2 reports causing crash
it's not that important now ... the most important thing is that I can make money because of the patent
I hope I wasn't wrong I went in for $ 3.54
gr8 price man
💯
Patience pays... the greedy always want to jump off first....
Timberrrrrr
super news!
What kind of news? It is dropping
Earning meeting just over. They are on track with their researches and their own covid 19 research.Thay have well enough money to operate till mid 2022 they said. Looks like everything good.
people they don't know what to do:)!they don't have the good info.
they'll be fine
why from +10% went to -10%????
Were the earnings bad?
no!
There did not hit there earnings mark. Probably why the price drop but they do have some good news for the future
yess!price go down!i will buy more and more of ARBUTUS $$shers
Bye bye arbutus
aaa it's ok whit earnings!Arbutus $$
https://seekingalpha.com/article/4364900-arbutus-story-isnt-recent-win-over-moderna?utm_source=marketchameleon.com&utm_medium=referral
this is big money bussines guys!
Welllll  maybe I will keep it... Sounds promising.
yes ,i'm selling my shers next year! entill next year i will buy more!
On Friday 12:00 am EST Q2 Earning report
So get up early and check pre market.
good news!WASHINGTON (Reuters) - U.S. President Donald Trump on Thursday will sign a long-awaited executive order aimed at boosting American production of medicines and medical equipment, and protecting the United States against shortfalls in a future pandemic, a top adviser said.
Go went gone
180% up last quarter 200% up this quarter. billions following quarter. flu season is coming to really complicate matters.!
Zack's rank #2
i'm not selling tomorrow!maybe octombrie
Earnings tomorrow big sell tomorrow sorry.
we sell when hit the 20$$$Arbus$$
$15 -$20 I am laughing so loud. That's why they get richer small players always loose.Greed...Take your profit and run.
  I need it to come up .49 cents to break even.. LOL
Let s go baby again
target?
Hopefully 6
...
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.